Parial Sonia
Consultant Psychiatrist, Raipur, Chhattisgarh, India.
Indian J Psychiatry. 2015 Jul;57(Suppl 2):S252-63. doi: 10.4103/0019-5545.161488.
Bipolar affective disorder in women is a challenging disorder to treat. It is unique in its presentation in women and characterized by later age of onset, seasonality, atypical presentation, and a higher degree of mixed episodes. Medical and psychiatric co-morbidity adversely affects recovery from the bipolar disorder (BD) more often in women. Co-morbidity, particularly thyroid disease, migraine, obesity, and anxiety disorders occur more frequently in women while substance use disorders are more common in men. Treatment of women during pregnancy and lactation is challenging. Pregnancy neither protects nor exacerbates BD, and many women require continuation of medication during the pregnancy. The postpartum period is a time of high risk for onset and recurrence of BD in women. Prophylaxis with mood stabilizers might be needed. Individualized risk/benefits assessments of pregnant and postpartum women with BD are required to promote the health of the women and to avoid or limit exposure of the fetus or infant to potential adverse effects of medication.
女性双相情感障碍是一种难以治疗的疾病。它在女性中的表现独具特点,具有发病年龄较晚、季节性、非典型表现以及较高比例的混合发作等特征。医学和精神疾病共病对女性双相情感障碍(BD)康复的不利影响更为常见。共病,尤其是甲状腺疾病、偏头痛、肥胖症和焦虑症在女性中更为频繁地出现,而物质使用障碍在男性中更为常见。孕期和哺乳期女性的治疗颇具挑战性。怀孕既不会保护也不会加重双相情感障碍,许多女性在孕期需要继续用药。产后时期是女性双相情感障碍发病和复发的高危期。可能需要使用心境稳定剂进行预防。需要对患有双相情感障碍的孕妇和产后女性进行个体化的风险/益处评估,以促进女性健康,并避免或限制胎儿或婴儿接触药物的潜在不良反应。